One shot to see clearly: cell therapy takes on corneal edema

NCT ID NCT07729137

NEW Not yet recruiting ⭐️ CURE ⭐️ Sponsor: Emmecell Source: ClinicalTrials.gov ↗

First seen Jul 27, 2026 · Last updated Jul 27, 2026

Summary

This phase 2 trial tests whether a single injection of EO2002, made from magnetic human corneal endothelial cells, can safely improve vision in people with corneal edema caused by endothelial dysfunction. Participants receive either a low or high dose of cells or a placebo injection. The main goal is to see if more people gain at least 15 letters on an eye chart 26 weeks after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a single injection of magnetic human corneal endothelial cells (mHCECs) called EO2002
What this could lead to
If it works, this could offer a one-time cell therapy to repair the cornea and restore vision, potentially reducing the need for corneal transplants.
What could go wrong
This is an early phase 2 trial, so the treatment may not improve vision or could cause side effects like inflammation or infection from the injection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORNEAL EDEMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Clinical Site 1

    Menlo Park, California, 94025, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.